biotech · Hypoglycemia · Diabetes Mellitus, Type 1 · XERS
Xeris Biopharma Holdings
Xeris Biopharma Holdings is a biotech organization headquartered in Chicago, USA. It trades on NYSE under ticker XERS. Primary therapeutic focus areas include Hypoglycemia, Diabetes Mellitus, Type 1, Insulin Hypoglycemia
Chicago, USA HQ
2005 Founded
496 Employees
Public company Type
XERS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Chicago, USA
- Founded
- 2005
- Employees
- 496
- Programs
- 16
- Drugs
- 12
- Patents
- 24
G-Pen Mini™ (glucagon injection)
Phase 2 · small molecule · Hypoglycemia
G-Pen Mini™ (glucagon injection) for Hypoglycemia is a Phase 2 program (small_molecule) at Xeris Biopharma Holdings with 1 ClinicalTrials.gov record(s).
Internal code XSMP-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xeris Biopharma Holdings
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hypoglycemia
- Status
- completed
- Trials
- 1